These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33031791)

  • 21. Artificial intelligence approach fighting COVID-19 with repurposing drugs.
    Ke YY; Peng TT; Yeh TK; Huang WZ; Chang SE; Wu SH; Hung HC; Hsu TA; Lee SJ; Song JS; Lin WH; Chiang TJ; Lin JH; Sytwu HK; Chen CT
    Biomed J; 2020 Aug; 43(4):355-362. PubMed ID: 32426387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.
    Aslam M; Ladilov Y
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies.
    Fagone P; Ciurleo R; Lombardo SD; Iacobello C; Palermo CI; Shoenfeld Y; Bendtzen K; Bramanti P; Nicoletti F
    Autoimmun Rev; 2020 Jul; 19(7):102571. PubMed ID: 32376402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
    Wang L; Peng X; Wang ZH; Cai J; Zhou FC
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19: lambda interferon against viral load and hyperinflammation.
    Andreakos E; Tsiodras S
    EMBO Mol Med; 2020 Jun; 12(6):e12465. PubMed ID: 32333818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combating devastating COVID-19 by drug repurposing.
    Pawar AY
    Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug repurposing and cytokine management in response to COVID-19: A review.
    Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
    Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Okamoto M; Toyama M; Baba M
    Antiviral Res; 2020 Oct; 182():104902. PubMed ID: 32739404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.
    Touret F; Gilles M; Barral K; Nougairède A; van Helden J; Decroly E; de Lamballerie X; Coutard B
    Sci Rep; 2020 Aug; 10(1):13093. PubMed ID: 32753646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning.
    Ackerman EE; Shoemaker JE
    Viruses; 2020 Sep; 12(10):. PubMed ID: 32993136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Existing Drugs Might Treat COVID-19.
    Abbasi J
    JAMA; 2020 Jun; 323(22):2239. PubMed ID: 32515802
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug repurposing against COVID-19: focus on anticancer agents.
    Ciliberto G; Mancini R; Paggi MG
    J Exp Clin Cancer Res; 2020 May; 39(1):86. PubMed ID: 32398164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canonical and Noncanonical Autophagy as Potential Targets for COVID-19.
    Bello-Perez M; Sola I; Novoa B; Klionsky DJ; Falco A
    Cells; 2020 Jul; 9(7):. PubMed ID: 32635598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3):169-172. PubMed ID: 32425222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.
    Zhou S; Zhou Z; Ding K; Yuan Y; Loftin C; Zheng F; Zhan CG
    Sci Rep; 2020 Jun; 10(1):10187. PubMed ID: 32576928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges of rapamycin repurposing as a potential therapeutic candidate for COVID-19: implications for skeletal muscle metabolic health in older persons.
    Lees MJ; Hodson N; Tinline-Goodfellow CT; Fung HJW; Elia A; Moore DR
    Am J Physiol Endocrinol Metab; 2022 Jun; 322(6):E551-E555. PubMed ID: 35521831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 treatment by repurposing drugs until the vaccine is in sight.
    Phadke M; Saunik S
    Drug Dev Res; 2020 Aug; 81(5):541-543. PubMed ID: 32227357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
    Orienti I; Gentilomi GA; Farruggia G
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR inhibition: a double-edged sword in patients with COVID-19?
    Ghasemnejad-Berenji M
    Hum Cell; 2021 Mar; 34(2):698-699. PubMed ID: 33527306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.
    Senger MR; Evangelista TCS; Dantas RF; Santana MVDS; Gonçalves LCS; de Souza Neto LR; Ferreira SB; Silva-Junior FP
    Mem Inst Oswaldo Cruz; 2020; 115():e200254. PubMed ID: 33027420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.